OPTHEA
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
OPTHEA
Industry:
Biopharma Biotechnology Health Care Life Science Medical Device Pharmaceutical
Founded:
1984-01-01
Address:
South Yarra, Victoria, Australia
Country:
Australia
Website Url:
http://www.opthea.com
Total Employee:
11+
Status:
Active
Contact:
+61398260399
Total Funding:
237.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Biotron
Biotron Limited is an Australian biotechnology company based in Sydney, NSW.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Current Employees Featured
MIKE TONROE CFO @ Opthea
CFO
IAN LEITCH DIRECTOR – CLINICAL RESEARCH @ Opthea
DIRECTOR – CLINICAL RESEARCH
MEGAN BALDWIN CEO, Managing Director @ Opthea
CEO, Managing Director
Judy J. Robertson Chief Commercial Officer @ Opthea
Chief Commercial Officer
2022-01-01
Jeremy Levin Chairman Of The Board @ Opthea
Chairman Of The Board
2021-01-01
RICHARD CHADWICK HEAD OF INTELLECTUAL PROPERTY @ Opthea
HEAD OF INTELLECTUAL PROPERTY
ANGUS TESTER SENIOR RESEARCH SCIENTIST @ Opthea
SENIOR RESEARCH SCIENTIST
Leon Serry Founder @ Opthea
Founder
MELINDA LOWE PROJECT MANAGER @ Opthea
PROJECT MANAGER
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-03 | Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD |
Official Site Inspections
http://www.opthea.com Semrush global rank: 6.83 M Semrush visits lastest month: 758
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Opthea"
Opthea: Developing Novel Therapies to Treat Vision-Threatening …
Opthea Limited. Suite 0403, Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia. Opthea US, Inc. 103 Carnegie Center Blvd Suite 300 Princeton, New Jersey 08540 United …See details»
About Us - Opthea | Pioneering Innovation to Improve Sight
Opthea is a global biopharmaceutical company pioneering therapeutic innovation in retinal diseases, including Wet AMD and DME treatment. Learn more about our mission and research.See details»
Investor Relations - Opthea Limited
Opthea Limited. Suite 0403, Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia. Opthea US, Inc. 103 Carnegie Center Blvd Suite 300 Princeton, New Jersey 08540 United …See details»
Opthea - Crunchbase Company Profile & Funding
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead …See details»
Corporate Governance - Opthea Limited
The Board of Directors of Opthea Limited is responsible for the corporate governance of the economic entity and guides and monitors the business and affairs of the Company on behalf of …See details»
Our Team - Opthea | Dedicated to Deliver Superior Vision
Dr. Baldwin has led the company as CEO and Managing Director from February 2014 to October 2023. She joined the company in 2008 and has held various positions, including Head of …See details»
Opthea - LinkedIn
Opthea | 6,669 followers on LinkedIn. Opthea is committed to improving vision in patients suffering with retinal eye diseases. | Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing ...See details»
Opthea Announces Executive Leadership Changes and Senior Hires
Sep 5, 2024 The following organizational changes further deepen the Company’s expertise in retina, expand its clinical capabilities, while advancing Opthea’s commercial readiness, in …See details»
Opthea - The Org
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Website. opthea.com. Headquarters. Toorak, Australia. …See details»
Opthea Company Profile - Office Locations, Competitors, Revenue …
Oct 4, 2024 Opthea has 5 employees across 2 locations and $125 k in annual revenue in FY 2024. See insights on Opthea including office locations, competitors, revenue, financials, …See details»
The billion-dollar gamble: Megan Baldwin’s vision to revolutionise …
Dec 19, 2024 She put her head down and went to work. They raised $17.5 million at a time when Opthea’s market capitalisation was only $8 million. Investors saw that, as successful as …See details»
Opthea Announces Decision to Discontinue Wet AMD Trials
3 hours ago Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern ... clinical research …See details»
Opthea Completes Drug Product PPQ Campaign - Opthea Limited
Feb 26, 2025 Opthea strongly recommends that professional investment advice be sought prior to such investments. Forward-Looking Statements. This announcement contains certain …See details»
Opthea on the brink after Phase-3 failure - forbes.com.au
Mar 24, 2025 Key Takeaways. In what was billed as the biggest Australian biotech readout in years, Opthea announced Monday morning the first of its two Phase-3 trials, COAST, involving …See details»
Opthea - businessabc
Feb 25, 2025 Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development …See details»
Opthea Announces Executive Leadership Changes and Senior
Sep 5, 2024 Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) …See details»
Our Culture - Opthea | Grounded in Compassion, Courage
Discover Opthea’s culture, built on compassion, courage, and commitment. Join a team dedicated to advancing retinal disease treatments and improving vision worldwide.See details»
How Does Opthea Work? – CanvasBusinessModel.com
Dec 19, 2024 Opthea generates revenue through licensing agreements, collaborations, and potential product sales. Opthea pursues partnerships and collaborations with pharmaceutical …See details»
Opthea Announces COAST Phase 3 Trial Topline Results - Opthea …
Mar 24, 2025 COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea considering impact of negative trial results under its …See details»
Opthea Limited: Transforming Retinal Disease Treatment
Jan 7, 2025 About Opthea Limited. Opthea Limited (ASX: OPT) is a leading biopharmaceutical company pioneering innovative therapies for retinal diseases such as wet age-related macular …See details»